高中性脂肪血症合併2型糖尿病患者のリポ蛋白粒子サイズ及び濃度に対するn-3系多価不飽和脂肪酸の効果の検討 by IDE, Kana & 井出, 佳奈
1 
 
Effect of n-3 polyunsaturated fatty acids on lipoprotein particle size 
and concentration in patients with type 2 diabetes and 
hypertriglyceridemia 
（高中性脂肪血症合併 2型糖尿病患者のリポ蛋白粒子サイズ及
び濃度に対する n-3系多価不飽和脂肪酸の効果の検討） 
 
 
 
 
 
 
 
 
千葉大学大学院医学薬学府 
先端医学薬学専攻 
（主任：横手幸太郎教授） 
井出佳奈  
2 
Background 
Over the past two decades, low-density lipoprotein cholesterol (LDL-C) has been established 
as a primary target for lipid-lowering therapies [1]. However, although numerous clinical 
trials have demonstrated that LDL-C lowering therapy with hydroxymethylglutaryl-CoA 
reductase inhibitors (statins) can reduce cardiovascular (CV) events [2,3], significant CV 
risks remain after achieving target LDL-C levels. Residual risk factors include 
hypertriglyceridemia, a low level of high-density lipoprotein (HDL) cholesterol, and 
increased small dense LDL or oxidized LDL.  
Diabetes is also a strong risk factor for CV events. Insulin resistance (IR) frequently leads 
to high very low-density lipoprotein (VLDL) and low HDL concentrations; therefore, 
residual risks are often critical in patients with diabetes. In particular, hypertriglyceridemia is 
a potent risk factor for cardiovascular disease (CVD) in Japanese patients with type 2 
diabetes [4]. However, the best strategy to target residual risk in patients with type 2 diabetes 
remains controversial. In the ACCORD lipid trial including 5,518 patients with diabetes and 
high CV risk, the addition of fenofibrate [5] to simvastatin failed to reduce CV events, with 
significant risk reduction only in patients with hypertriglyceridemia and low HDL. In 
addition, fibrates often cause adverse effects when administered in combination with statins, 
especially in patients with renal dysfunction. The JELIS study [6] revealed that 
eicosapentaenoic acid (EPA) reduced residual CV risks, although no effects were observed in 
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patients with dysglycemia [7]. Therefore, lipid-lowering therapies that can be used safely and 
effectively in statin-treated patients with diabetes are required. 
In addition to lipoprotein concentrations, the importance of particle quality, such as size 
and function, has been recently considered. Small dense LDL particles are more atherogenic 
because of their lower binding affinity for the LDL receptor, longer plasma half-life, higher 
penetration into the arterial wall, and greater susceptibility to oxidative stress [8]. Previous 
studies have revealed that small dense LDL is strongly associated with CV events [9]. 
Furthermore, large VLDL is also considered atherogenic [10, 11].  
Conversely, n-3 polyunsaturated fatty acids (n-3 PUFAs), predominantly EPA and 
docosahexaenoic acid (DHA), are widely used as a triglyceride (TG) lowering therapy in 
patients with type 2 diabetes and hypertriglyceridemia [7]. EPA/DHA at 4 g/day, but not EPA 
at either 2 or 4 g/day [12], improved LDL particle size in patients with hypertriglyceridemia 
[13]. Moreover, a previous report revealed that the combination of n-3 PUFAs and dipeptidyl 
peptidase-4 (DPP-4) inhibitors was expected to improve glycemic control [14]. Therefore, 
n-3 PUFAs are expected to have multiple effects on the reduction of residual CV risks in 
statin-treated patients with type 2 diabetes. 
Accordingly, the aim of this study was to evaluate the effects of n-3 PUFAs on residual 
CV risk factor reduction in a real-life setting. We assessed the effects of n-3 PUFAs on 
lipoprotein particle size, concentration, and glycemic control in Japanese patients with type 2 
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diabetes and hypertriglyceridemia who had achieved target the LDL-C level and glycemic 
control with statins and DPP-4 inhibitors. 
 
Methods 
Study design 
This was a multicenter, prospective, open-label, single arm study. The study protocol was 
approved by the following Institutional Review Boards: Institutional Review Board of Chiba 
University Hospital (ID number: G25019) and National Hospital Organization Chiba Medical 
Center Research Review Board. Tokuyama Clinic was assessed at the Institutional Review 
Board of Chiba University Hospital, which was the centralized IRB (ID number: N25031). 
The protocol was registered at 
https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000016078  
(UMIN-ID: UMIN000013776). Signed written informed consent was obtained from all 
patients. The study was conducted in full compliance with the articles of the Declaration of 
Helsinki. 
 
Patients 
This study was conducted in Japanese patients with type 2 diabetes treated with statin and 
DPP-4 inhibitors, whose TG levels were not sufficiently controlled. The main inclusion 
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criteria were: (1) treatment with statins and DPP-4 inhibitors, with an LDL-C level < 120 
mg/dL (the target LDL-C level for Japanese patients with diabetes in primary prevention 
[15]), and a glycated hemoglobin (HbA1c) level < 8 %; (2) fasting TG levels of ≥ 150 mg/dL 
twice, with at least 4 weeks between tests; and (3) age ≥ 20 years and < 80 years. The main 
exclusion criteria were: (1) TG level of ≥ 1000 mg/dL or HDL-C level of ≤ 30 mg/dL; (2) 
users of n-3 PUFAs, nicotinic acid, or fibrate; (3) pioglitazone use; (4) met the 
contraindication criteria of n-3 PUFAs; (5) hypersensitivity to EPA or DHA; (6) familial 
hypercholesterolemia; (7) diagnosed with type 1 diabetes; (8) recent history (within 6 
months) of diabetic ketosis; (9) diagnosed with a severe infectious disease, was perioperative, 
or had experienced trauma; (10) serum creatinine level of ≥ 1.5 mg/dL (male) or 1.3 mg/dL 
(female); (11) recent history (within 6 months) of stroke or myocardial infarction, (12) 
diagnosed with cancer; or (13) pregnant, possibly pregnant, or lactating. 
 
Study procedures 
After a 12-week observation period, patients received 12 weeks of treatment with n-3 PUFAs 
at 4 g/day (EPA 1860 mg and DHA 1500 mg; Lotriga
®
, Takeda Pharmaceutical Company 
Limited, Tokyo, Japan). Changes in lipid-altering agents were prohibited during the 
administration period. Antidiabetic medication could be changed, with the exception of 
pioglitazone. All patients in this study were educated regarding dietary and physical therapy 
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by their doctor and dietitian when they were enrolled in the study. They continued the same 
diet and exercise during both the observation period and the intervention period. We verbally 
confirmed patient drug adherence every 4 weeks during the study period. 
 
Study endpoints 
The primary endpoint was change in LDL particle size. The secondary endpoints were 
changes in lipoprotein particle size and concentration, lipoprotein insulin resistance (LPIR) 
score, which has strong associations with IR indices, glycoprotein acetylation (GlycA), which 
was an inflammatory marker, LDL-C, HDL-C, TG concentration, HbA1c, fasting plasma 
glucose (FPG), EPA/AA ratio, DHA/AA ratio, and safety value. 
 
Measurements 
Overnight fasting blood samples were collected prior to and 4, 8, and 12 weeks after the 
administration of n-3PUFAs. Lipoprotein sizes and concentrations were measured prior to 
and 12 weeks after administration using the nuclear magnetic resonance (NMR)-based 
Lipoprofile-III
®
 method (Labcorp, Cary, NC) and a high performance liquid chromatography 
(HPLC)-based method (LipoSEARCH, Skylight Biotech, Tokyo, Japan).  
 
Statistical analysis 
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Data represent the means ± standard deviation (SD). Statistical analysis was performed using 
JMP Pro 12 (SAS, Cary, NC). A Wilcoxon signed-rank test was used for statistical analysis of 
clinical parameters and lipoprotein profiles prior to and following treatment. The Spearman 
rank correlation coefficient was used to analyze correlations between different variables. 
Differences were considered statistically significant when P < 0.05. 
 
Results 
A total of 14 patients were enrolled in this study. Of these, two were withdrawn from the 
study, as one patient was treated with pioglitazone during the administration period, and one 
patient missed a fasting blood test. The rate of drug adherence exceeded 75%. 
The baseline characteristics of the patients are shown in Table 1. The majority of patients 
achieved the targeted LDL-C level. However, their TG levels remained uncontrolled. There 
were no statistically significant changes during the observation period. Clinical parameters 
prior to and following treatment with n-3 PUFAs are presented in Table 2 and Table S1. There 
were no significant differences in body mass index (BMI) or blood pressure before and after 
treatment. Fasting plasma glucose levels unchanged, whereas HbA1c levels increased (P = 
0.038). Treatment with n-3 PUFAs significantly decreased the total cholesterol (P < 0.001), 
LDL-C (P = 0.003), and TG (P < 0.001) concentrations. The EPA/AA and DHA/AA ratios 
significantly increased (both P = 0.008) after treatment. 
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Table 3 displays the changes in lipoprotein particle size and concentration. Although LDL 
and HDL size remained unchanged, VLDL size significantly decreased (P < 0.001). Large 
VLDL and chylomicron concentrations significantly decreased (P < 0.001) and the small 
LDL concentration showed a tendency to decrease. Similarly, large VLDL and very small 
LDL particle numbers significantly decreased (P = 0.001 and P = 0.007, respectively; Table 
S2). In addition, we confirmed a significant correlation between the NMR and HPLC 
methods with respect to lipoprotein particle size (Fig. 1). 
Figure 2 displays the changes in the lipoprotein subclass ratios. After treatment, the 
percentage of large VLDL decreased from 15.6% to 3.2% whereas small VLDL increased 
from 37.0% to 50.7% (Fig. 2A). The ratio of large to small VLDL significantly decreased 
from 0.79 to 0.09 (P < 0.001). Large LDL increased from 8.4% to 13.5% whereas small LDL 
decreased from 75.6% to 70.5% (Fig. 2B). The ratio of large to small LDL significantly 
increased from 0.14 to 0.21 (P = 0.042). Large HDL increased from 18.4% to 21.0% whereas 
medium HDL decreased from 13.2% to 11.8% (Fig. 2C). The ratio of large to medium HDL 
tended to increase, from 7.5 to 9.1 (P = 0.79). In addition, LPIR scores significantly 
improved (P = 0.001) after treatment with n-3 PUFAs whereas GlycA remained unchanged 
(P = 0.129; Table 3). 
There were no severe adverse events related to treatment and n-3 PUFAs had no effect on 
liver or renal function (Table 2). One patient complained of mild constipation and another of 
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a symptom similar to hypoglycemia. Both conditions were considered to be unrelated to 
treatment. 
Figure 3 displays the correlations between the EPA/AA and DHA/AA ratios and the 
lipoprotein particle concentrations and LPIR scores. The small LDL concentration was 
significantly negatively correlated with the EPA/AA (r = −0.548, P = 0.012) and DHA/AA (r 
= −0.583, P = 0.007) ratios (Fig. 3A). Both the large VLDL concentration and LPIR score 
were significantly negatively correlated with the EPA/AA ratio (r = −0.515, P = 0.020 and r = 
−0.454, P = 0.044, respectively; Fig. 3B and 3C). Table 4 displays the baseline clinical 
parameters in the subgroups exhibiting decreased and increased very small LDL particle 
concentrations. In the former, the baseline TG level was significantly higher (P = 0.026). 
Figure S1 shows the relationship between HbA1c and DHA/AA or EPA/AA ratio. Notably, 
change of HbA1c was positively correlated with change of DHA/AA (r = 0.779, P = 0.023) 
but not EPA/AA ratio. 
 
Discussion 
In this study, we found that n-3 PUFAs could reduce the ratio of atherogenic lipoprotein 
particles and reduce the LPIR score in patients with type 2 diabetes, whereas there were no 
marked changes in LDL particle size and concentration. These findings are clinically 
important in two respects: (1) n-3 PUFAs may safely reduce residual CV risks in patients 
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with type 2 diabetes who were treated with statins and achieved target LDL-C levels, and (2) 
n-3 PUFAs might reduce lipoproteins associated with IR in patients with type 2 diabetes.  
There are few studies that address patients who have achieved LDL-C target levels 
through statin use, although some studies have demonstrated that statins and n-3 PUFAs 
improved lipoprotein particle size and number [16–18]. Dunbar et al. [19] reported that 6 
weeks of treatment with 4 g/day n-3 PUFAs reduced atherogenic lipoprotein particle 
concentrations and increased LDL size in patients treated with statins. Their results indicated 
that changes in LDL particle size were correlated with changes in the TG level. Conversely, 
in our study, n-3 PUFAs did not improve LDL particle size. A potential explanation for this 
difference is that primary TG levels in this study (≥ 150 mg/dL) were not as high as in the 
previous study (≥ 200 mg/dL). However, small LDL particles were significantly decreased in 
patients with primary high TG in our study. These results thus support the conclusion that the 
TG level mainly determines LDL particle size [20].  
Some studies have reported increased LDL-C concentrations after n-3 PUFA therapy in 
patients with hypertriglyceridemia [21], because n-3 PUFAs form smaller VLDL particles, 
which are more rapidly converted to LDL than large VLDL particles [22]. In contrast, the 
LDL-C concentration did not increase after treatment in our study. A possible explanation for 
this result may be that statin coadministration activated LDL receptors, which led to 
enhanced clearance of intermediate density lipoprotein and LDL [23]. Furthermore, the 
11 
LDL-C level is correlated with the TG level. When TG ≥ 133 mg/dL, LDL-C levels increase 
as TG levels decrease; however, in the range of TG < 133 mg/dL, LDL-C levels decrease as 
TG levels decrease [24]. In our study, the TG level markedly decreased (from 195.7 ± 49.9 to 
128.7 ± 58.8 mg/dL), which may explain why the LDL-C concentration did not increase. 
N-3 PUFAs significantly decreased VLDL particle size and concentration, especially for 
large VLDL. In patients with type 2 diabetes, hypertriglyceridemia causes both 
overproduction of TG-rich VLDL and impaired VLDL clearance [25]. TG-rich VLDL is 
larger, and can promote endothelial dysfunction by inhibiting endothelium-dependent 
vasorelaxation [10,11]. In addition, increased large VLDL promotes cholesteryl ester transfer 
protein-catalyzed TG exchange from VLDL to LDL. TG-rich LDL is a substrate for hepatic 
lipase, resulting in the formation of small dense LDL. For this reason, large VLDL is 
atherogenic, and reduced large VLDL is considered an anti-atherogenic change. 
The LPIR score constitutes a novel marker associated with IR that comprises six 
lipoprotein parameters (VLDL, LDL, and HDL particle sizes and large VLDL, small LDL, 
and large HDL particle concentrations) as measured by NMR. The LPIR score was strongly 
correlated with the homeostasis model assessment of IR (HOMA-IR) and glucose disposal 
rate in nondiabetic patients [26]. Supplementation of n-3 PUFAs improved IR in an animal 
model, as measured by the HOMA-IR [27]. In the present study, the LPIR score significantly 
decreased after administration of n-3 PUFAs, indicating that n-3 PUFAs can decrease 
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IR-related lipoprotein particles. However, a limitation of our study is that we did not examine 
other IR measures, such as the HOMA-IR. 
The effect of n-3 PUFAs on glycemic control in patients with type 2 diabetes is 
controversial [28–30]. Iwasaki et al. [14] reported that reduction of HbA1c by DPP-4 
inhibitors significantly correlates with serum EPA and DHA levels; therefore, DPP-4 
inhibitors and n-3 PUFAs were expected to be a good combination. However, in our study, 
the HbA1c level slightly increased during the treatment period. This may have occurred in 
part because of the short treatment duration and use of statins. Furthermore, unlike a previous 
report [14], patients in the present study were also treated with other anti-diabetic 
medications, reflecting the clinical settings. These factors are thought to deteriorate glycemic 
control. In addition, our study revealed that the increase in HbA1c was positively correlated 
with increase in DHA/AA. Contrary to previous studies, DHA might thus increase HbA1c in 
some situations; therefore, care should be taken regarding the deterioration of glycemic 
control in statin-treated patients with diabetes.  
This study has several limitations. First, this was an open-label and single arm design 
study. Therefore, a randomized controlled study is required. However, the present study 
showed that n-3 PUFAs changed the ratio of lipoprotein particles in favor of less atherogenic 
particles. Moreover, the EPA/AA and DHA/AA plasma ratios were significantly negatively 
correlated with atherogenic particle concentrations. There were also no statistically 
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significant changes in clinical parameters during the observation period. For these reasons, 
we consider that these effects were not the result of diet or other medications, but arose 
following the administration of n-3 PUFAs. Second, the small number of patients may be 
insufficient to evaluate changes in lipoprotein particles. However, this was the first study to 
evaluate the effects of DPP-4 inhibitor, statin, and n-3 PUFA combination therapy on 
lipoprotein particle and glycemic control in patients with type 2 diabetes and 
hypertriglyceridemia. Larger studies will be required in the future to confirm our findings. 
Third, we could not take account of the effect of diet or nutraceuticals on lipoprotein profiles. 
Recent reports revealed that several nutraceuticals have lipid-lowering effects [31-33] and are 
related to likelihood of arteriosclerotic disease [34]. In this study, all patients were educated 
regarding diet therapy, however, we could not collect the actual data related to the usual diet 
and nutraceuticals. Therefore, we could not completely exclude the effect of dietary factor. 
Lastly, we have not evaluated the effects of n-3 PUFAs for arteriosclerotic diseases, due to 
the short treatment duration. 
 
Conclusions 
N-3 PUFAs improved atherogenic lipoprotein particle size and concentration. This treatment 
changed the ratio of lipoprotein subclasses to less atherogenic values, even in patients that 
had achieved target LDL-C levels and glycemic control. N-3 PUFAs may reduce residual CV 
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risk factors in patients with type 2 diabetes and hypertriglyceridemia. 
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Figure titles and legends 
Fig. 1 Lipoprotein particle size correlations using nuclear magnetic resonance (NMR) and 
high performance liquid chromatography (HPLC) 
 
Fig. 2 Changes in lipoprotein subclass ratios after n-3 PUFA treatment. Panels show the 
subclass percentages for (A) very low-density lipoprotein (VLDL), (B) low-density 
lipoprotein (LDL), and (C) high-density lipoprotein (HDL). IDL, intermediate density 
lipoprotein 
 
Fig. 3 Correlations between the EPA/AA and DHA/AA ratios and lipoprotein particle 
concentrations and lipoprotein insulin resistance (LPIR) scores. LDL, low-density 
lipoprotein; VLDL, very low-density lipoprotein 
 
 
Additional files 
Table S1 Changes in clinical parameters 4 and 8 weeks after the administration of n-3 
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polyunsaturated fatty acids (n-3 PUFAs) 
Table S2 Changes in lipoprotein particles after n-3 polyunsaturated fatty acid (n-3 PUFA) 
administration measured by high performance liquid chromatography  
Fig. S1 Correlations between ΔHbA1c and the ratios of ΔDHA/AA and ΔEPA/AA. Data 
present the changes in HbA1c, DHA/AA ratio, and EPA/AA ratio from baseline to the end of 
the intervention period 
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Table 1 Baseline characteristics 
 
Characteristic n = 12 
Age (years) 65 ± 11 
Male (%) 6 (50) 
BMI (kg/m²) 28.2 ± 5.4 
SBP (mmHg) 141 ± 7.6 
DBP (mmHg) 74.9 ± 11.0 
HbA1c (%) 6.9 ± 0.70 
FPG (mg/dL) 139.5 ± 40.5  
TC (mg/dL) 176.4 ± 26.8 
LDL-C (mg/dL) 97.3 ± 25.8 
HDL-C (mg/dL) 45.5 ± 9.1 
TG (mg/dL) 184.7 ± 34.8 
EPA/AA  0.30 ± 0.19 
DHA/AA  0.75 ± 0.16 
AST (IU/L) 24.5 ± 13.0 
ALT (IU/L) 32.5 ± 31.7 
Cre (mg/dL) 0.81 ± 0.30 
26 
Antidiabetic medications (%)  
  DPP-4 inhibitor 12 (100) 
  Metformin 6 (50) 
 Glimepiride  3 (25) 
  Repaglinide  1 (8.3) 
  Miglitol  3 (25) 
 Ipragliflozin  1 (8.3) 
  Insulin Aspart  2 (16.6) 
  Insulin Detemir  1 (8.3) 
  Insulin Glargine  1 (8.3) 
Hypolipidemic agents    
  Rosuvastatin  6 (50) 
  Atorvastatin  2 (16.6) 
 Pravastatin  2 (16.6) 
  Pitavastatin  2 (16.6) 
Antihypertensive agents  9 (75) 
Microvascular complications 
  Diabetes nephropathy    
Macrovascular complications 
 
3 (25) 
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  Cerebral infarction 1 (8.3) 
Data represent the means ± standard deviation or n (%). BMI, body mass index; SBP, systolic 
blood pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; FPG, fasting 
plasma glucose; TC, total cholesterol; LDL-C, low-density lipoprotein cholesterol; HDL-C, 
high-density lipoprotein cholesterol; TG, triglyceride; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; Cre, creatinine 
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Table 2 Changes in clinical parameters after administration of n-3 PUFAs 
 
Parameter Before After P-value 
BMI (kg/m²) 28.2 ± 5.4 28.0 ± 5.4 0.700 
SBP (mmHg) 141.0 ± 7.6 136.0 ± 11.3 0.113 
DBP (mmHg) 74.9 ± 11.0 77.9 ± 11.0 0.334 
HbA1c (%) 6.9 ± 0.5 7.1 ± 0.6 0.038 
FPG (mg/dL) 132.3 ± 18.7 134.7 ± 25.8 0.664 
TC (mg/dL) 171.3 ± 21.5 150.5 ± 16.0 <0.001 
LDL-C (mg/dL) 90.3 ± 17.1 79.4 ± 11.4 0.003 
HDL-C (mg/dL) 44.9 ± 9.5 45.5 ± 11.3 0.763 
TG (mg/dL) 195.7 ± 49.9 128.7 ± 58.8 <0.001 
EPA/AA 0.30 ± 0.19 1.30 ± 0.30 0.008 
DHA/AA 0.75 ± 0.16 1.29 ± 0.32 0.008 
AST (IU/L) 21.6 ± 6.0 21.8 ± 5.2 0.828 
ALT (IU/L) 24.2 ± 6.0 25.4 ± 7.2 0.977 
Cre (mg/dL) 0.81 ± 0.32 0.83 ± 0.36 0.539 
Data represent the means ± standard deviation. P-values represent differences observed 
before and after administration of n-3 PUFAs. BMI, body mass index; SBP, systolic blood 
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pressure; DBP, diastolic blood pressure; HbA1c, glycated hemoglobin; FPG, fasting plasma 
glucose; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, high 
density lipoprotein cholesterol; TG, triglyceride; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; Cre, creatinine 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
30 
Table 3 Changes in lipoprotein particles after n-3 PUFA administration measured by  
nuclear magnetic resonance  
 
Lipoprotein particle Before After P-value 
VLDL size (nm) 56.3 ± 7.14 45.2 ± 4.01 <0.001 
LDL size (nm) 20.0 ± 0.306 20.1 ± 0.361 0.154 
HDL size (nm) 9.13 ± 0.302 9.17 ± 0.382 0.535 
Total VLDL & CM concentrations (nmol/L) 73.6 ± 22.0 75.6 ± 38.5 0.850 
  Large VLDL & CM (nmol/L) 10.4 ± 4.31 2.18 ± 1.81 <0.001 
  Medium VLDL (nmol/L) 34.6 ± 11.2 36.5 ± 25.6 0.850 
  Small VLDL (nmol/L) 28.7 ± 15.3 36.8 ± 20.7 0.380 
Total LDL concentration (nmol/L) 1040 ± 237 995 ± 215 0.266 
  Large LDL (nmol/L) 98.9 ± 145 142 ± 131 0.142 
  IDL (nmol/L) 158 ± 75.8 155 ± 87.5 0.850 
  Small LDL (nmol/L) 780 ± 210 698 ± 170 0.151 
Total HDL concentration (nmol/L) 34.2 ± 4.42 32.0 ± 5.31 0.110 
  Large HDL (nmol/L) 6.25 ± 2.14 6.74 ± 3.26 0.531 
  Medium HDL (nmol/L) 4.73 ± 5.00 3.93 ± 3.60 0.557 
  Small HDL (nmol/L) 23.2 ± 4.71 21.3 ± 3.42 0.233 
31 
LPIR score 65.1 ± 11.1 40.5 ± 14.8 0.001 
GlycA 411 ± 50.5 432 ± 49.1 0.129 
Data represent the means ± standard deviation. P-values represent differences observed 
before and after n-3 PUFA administration. VLDL, very low-density lipoprotein; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein; CM, chylomicron; IDL, intermediate 
density lipoprotein; LPIR, lipoprotein insulin resistance; GlycA, glycoprotein acetylation 
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Table 4 Baseline clinical parameters in very small LDL particle subgroups with decreased 
and increased concentration 
 
Parameter Very small LDL particle concentration  
  Patients with decrease 
(n = 9) 
Patients with increase 
(n = 3) 
P-value 
Age (years) 62.6 ± 11.1 72.0 ± 4.00 0.194 
BMI (kg/m²) 28.4 ± 5.34 27.9 ± 6.89 1.000 
TC (mg/dL) 176 ± 26.8 178 ± 32.7 1.000 
LDL-C (mg/dL) 95.8 ± 26.1 102 ± 30.0 1.000 
HDL-C (mg/dL) 44.1 ± 8.12 50.0 ± 12.7 0.350 
TG (mg/dL) 195 ± 34.6 154 ± 5.86 0.026 
Data represent the means ± standard deviation. P-values represent differences between the 
two groups. Lipoprotein particle concentrations were measured using high performance 
liquid chromatography. BMI, body mass index; TC, total cholesterol; LDL-C, low-density 
lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; TG, triglyceride. 
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Table S1. Changes in clinical parameters 4 and 8 weeks after the administration of n-3 
polyunsaturated fatty acids (n-3 PUFAs) 
Parameter 4 weeks P-value 8 weeks P-value 
HbA1c (%) 6.9 ± 0.5 0.766 6.9 ± 0.5 0.328 
FPG (mg/dL) 137.5 ± 20.2 0.232 132.9 ± 18.8 0.904 
TC (mg/dL) 151.2 ± 22.0 0.002 154.6 ± 17.0 0.001 
LDL-C (mg/dL) 76.3 ± 19.3 0.002 82.6 ± 14.9 0.064 
HDL-C (mg/dL) 45.5 ± 12.7 0.528 44.0 ± 8.2 0.454 
TG (mg/dL) 151.4 ± 58.9 0.005 135.4 ± 45.5 0.003 
AST (IU/L) 22.8 ± 8.8 1.000 27.1 ± 10.2 0.078 
ALT (IU/L) 27.7 ± 9.2 0.102 27.6 ± 9.4 0.551 
Cre (mg/dL) 0.83 ± 0.35 0.640 0.85 ± 0.44 0.190 
Data represent the mean ± standard deviation. P-values represent differences observed before 
and 4 or 8 weeks after n-3 PUFA administration. HbA1c, glycated hemoglobin; FPG, fasting 
plasma glucose; TC, total cholesterol; LDL-C, low density lipoprotein cholesterol; HDL-C, 
high density lipoprotein cholesterol; TG, triglyceride; AST, aspartate aminotransferase; ALT, 
alanine aminotransferase; Cre, creatinine. 
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Table S2. Changes in lipoprotein particles after n-3 polyunsaturated fatty acid (n-3 PUFA) 
administration measured by high performance liquid chromatography  
 
Lipoprotein particle Before After P-value 
VLDL particle size (nm) 51.1 ± 2.21 47.4 ± 3.39 0.004 
LDL particle size (nm) 25.7 ± 0.790 25.9 ± 0.686 0.079 
HDL particle size (nm) 10.4 ± 0.173 10.5 ± 0.304 0.065 
CM particle number (nmol/L) 2.27 ± 1.43 0.820 ± 0.620 <0.001 
Total VLDL particle number (nmol/L)  168 ± 36.2 138 ± 56.3 0.012 
 Large VLDL (nmol/L) 73.7 ± 14.2 50.7 ± 24.7 0.001 
 Medium VLDL (nmol/L) 54.9 ± 14.2 48.4 ± 22.3 0.110 
 Small VLDL (nmol/L) 39.1 ± 12.2 38.8 ± 12.3 1.000 
Total LDL particle number (nmol/L)  1080 ± 213 960 ± 167 0.003 
 Large LDL (nmol/L) 148 ± 26.7 148 ± 23.4 1.000 
 Medium LDL (nmol/L) 441 ± 97.8 396 ± 70.4 0.002 
 Small LDL (nmol/L) 306 ± 78.4 259 ± 64.4 0.005 
 Very small LDL (nmol/L) 182 ± 35.2 157 ± 38.7 0.007 
Total HDL particle number (nmol/L) 14600 ± 1670 13700 ± 1690 0.007 
 Very large HDL (nmol/L) 185 ± 50.6 190 ± 63.3 0.519 
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 Large HDL (nmol/L) 828 ± 381 1020 ± 548 0.034 
 Medium HDL (nmol/L) 3130 ± 631 2920 ± 760 0.016 
 Small HDL (nmol/L) 5370 ± 486 4770 ± 591 <0.001 
 Very small HDL (nmol/L) 5080 ± 552 4830 ± 605 0.176 
Data represent the mean ± standard deviation. P-values represent differences observed before 
and after administration of n-3 PUFAs. VLDL, very low-density lipoprotein; LDL, 
low-density lipoprotein; HDL, high-density lipoprotein; CM, chylomicron. 
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Figure 1 
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Figure 2 
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Figure 3 
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Figure S1 
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